Metilfenidato en el tratamiento del trastorno por déficit de atención e hiperactividad

  1. Paula Cilleros Holgado 1
  2. Rubén Jurado Escobar 1
  3. Rocío Piñero Pérez 1
  1. 1 Universidad Pablo de Olavide
    info

    Universidad Pablo de Olavide

    Sevilla, España

    ROR https://ror.org/02z749649

Journal:
MoleQla: revista de Ciencias de la Universidad Pablo de Olavide

ISSN: 2173-0903

Year of publication: 2020

Issue: 39

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: MoleQla: revista de Ciencias de la Universidad Pablo de Olavide

Abstract

El trastorno por déficit de atención e hiperactividad (TDAH o ADHD por sus siglas en inglés) es un trastorno de origen neuropsicológico caracterizado fundamentalmente por la falta de atención e hiperactividad-impulsividad de los individuos afectados. Existen diversas estrategias farmacológicas para su tratamiento, divididas en psicoestimulantes y no psicoestimulantes, entre las que destacan el metilfenidato por ser el tratamiento de elección para este trastorno. Sin embargo, este fármaco presenta múltiples efectos secundarios que afectan al desarrollo normal del paciente y su mecanismo de acción es complejo, por lo que se requieren mejoras y un mayor estudio sobre el mismo.

Bibliographic References

  • R. L. Cerván and J. F. Romero-Pérez, “Electronic Journal of Research in Educational Psychology.”, Electron J Res Educ Psychol, vol. 8, no. 22, pp. 1303-1338, 2010, Disponible en: https://www.redalyc.org/articulo.oa?id=2931/293122000017.
  • R. A. Barkley, K. M. Smith, M. Fischer, “ADHD risk genes involved in dopamine signaling and metabolism are associated with reduced estimated life expectancy at young adult follow-up in hyperactive and control children”, Am J Med Genet B Neuropsychiatr Genet, vol. 180, no. 3, pp. 175-185, Apr 2019, doi:10.1002/ajmg.b.32711.
  • A. Sharma and J. Couture, “A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)”, Ann Pharmacother, vol. 48, no. 2, pp. 209-225, Feb 2014, doi:10.1177/1060028013510699.
  • T. A. Pickens, S. P. Khan, D. J. Berlau, “White noise as a possible therapeutic option for children with ADHD”, Complement Ther Med, vol. 42, pp. 151-155, Feb 2019, doi:10.1016/j.ctim.2018.11.012.
  • E. Sciberras, M. Mulraney, D. Silva, D. Coghill, “Prenatal Risk Factors and the Etiology of ADHD—Review of Existing Evidence”, Curr Psychiatry Rep, vol. 19, no. 1, Jan 2017, doi:10.1007/s11920-017-0753-2.
  • G. Donzelli, A. Carducci, A. Llopis-Gonzalez, M. Verani, A. LlopisMorales, L. Cioni, M. M. Suárez-Varel, “The Association between Lead and Attention-Deficit/Hyperactivity Disorder: A Systematic Review”, Int J Environ Res Public Health, vol. 16, no. 3, pp. 382, Jan 2019, doi:10.3390/ijerph16030382.
  • K. Larson, S. A. Russ, R. S. Kahn, N. Halon, “Psychopharmacology of ADHD in pediatrics: Current advances and issues”, Neuropsychiatr Dis Treat, vol. 5, pp. 171-181, Apr 2009, doi:10.2147/ndt.s4075.
  • J. Cheng, Z. Xiong, L. J. Duffney, J. Wei, A. Liu, S. Liu, G. J. Chen, Z. Yan, “Methylphenidate Exerts Dose-Dependent Effects on Glutamate Receptors and Behaviors”, Biol Psychiatry, vol. 76, no. 12, pp. 953-962, Dec 2014, doi:10.1016/j.biopsych.2014.04.003.
  • J. Flórez, Farmacología humana, Masson, 2ª Ed, pp. 499-500, 1992.
  • C. Rozas, C. Carvallo, D. Contreras , M. Carreño, G. Ugarte, R. Delgado, M. L. Zeise, B. Morales. “Methylphenidate amplifies long-term potentiation in rat hippocampus CA1 area involving the insertion of AMPA receptors by activation of β-adrenergic and D1/D5 receptors” Neuropharmacology, vol. 99, pp. 15-27, Dec 2015, doi: 10.1016/j.neuropharm.2015.07.003.
  • K. R. Urban, Y. Li, W. Gao, “Treatment With a Clinically-Relevant Dose of Methylphenidate Alters NMDA Receptor Composition and Synaptic Plasticity in the Juvenile Rat Prefrontal Cortex” Neurobiol Learn Mem, vol. 101, pp. 65-74, Mar 2013, doi: 10.1016/j.nlm.2013.01.004.
  • E. Grünblatt, J. Bartl, S. Walitza, “Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways”, Transl Psychiatry, vol. 1, no. 8, pp. 51, Mar 2018, doi: 10.1038/s41398-018-0096-8.
  • A. P. Groenman, L. J. S. Schweren, A. Dietrich, P. J. Hoekstra, “An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder”, Expert Opin Drug Saf, vol. 16, no. 4, pp. 455-464, Apr 2017, doi: 10.1080/14740338.2017.1301928.
  • J. Y. Shin, E. E. Roughead, B. J. Park, N. L. Pratt, “Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study”, BMJ, vol. 353, pp. i3123, Jun 2016, doi: 10.1136/bmj.i3123.
  • M. Ravi and A. Ickowicz, “Epilepsy, AttentionDeficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence”, J Can Acad Child Adolesc Psychiatry, vol. 25, no. 1, pp. pp. 50-58, Feb 2016, PMID: 27047557.
  • H. Hovshoff, T. Banaschewski, J. K. Buitelaar, S. Carucci, D. Coghill, M. Danckaerts, R. W. Dittmann, B. Falissard, D. G. Grimshaw, C. Hollis, S. Inglis, K. Konrad, E. Liddle, S. McCarthy, P. Nagy, M. Thompson, I. C. Wong, A., Zuddas, E. J. Sonuga-Barke, “Reports of Perceived Adverse Events of Stimulant Medication on Cognition, Motivation, and Mood: Qualitative Investigation and the Generation of Items for the Medication and Cognition Rating Scale.”, J Child Adolesc Psychopharmacol, vol. 26, no. 6, pp. 537-547, Aug 2016, doi: 10.1089/cap.2015.0218.
  • A. Charach, E. Yeung, T. Climans, E. Lillie, “Childhood AttentionDeficit/Hyperactivity Disorder and Future Substance Use Disorders: Comparative Meta-Analyses”, J Am Acad Child Adolesc Psychiatry, vol. 50, no. 1, pp. 9-21, Jan 2011, doi: 10.1016/j.jaac.2010.09.019.
  • K. M. Kidwell, T. R. Van Dyk, A. Lundahl, T. D. Nelson, “Stimulant Medications and Sleep for Youth With ADHD: A Meta-analysis.”, Pediatrics, vol. 36, no. 6, pp. 1144-1153, Dec 2015, doi: 10.1542/peds.2015-1708.
  • L. E. MacKenzie, S. Abidi, H. L. Fisher, L. Propper, A. Bagnell, J. Morash-Conway, J. M. Glover, J. Cumby, T. Tomas, F. SchultzeLutter, K. Pajer, M. Alda, R Uher, “Stimulant Medication and Psychotic Symptoms in Offspring of Parents With Mental Illness.”, Pediatrics, vol. 137, pp. e20152486, doi: 10.1542/peds.2015-2486
Data source: Dialnet